Advanced in Marginal Zone Lymphoma (MZL)

Dr. Bruce D. Cheson

Hematology | Hematology Oncology | Oncology
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
Accepting New Patients
Advanced in Marginal Zone Lymphoma (MZL)
American Oncology Partners PA
6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Bethesda, Maryland. Dr. Cheson is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

His clinical research consists of co-authoring 274 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Oncology
Licenses
Internal Medicine in DC
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

AMERICAN ONCOLOGY PARTNERS PA
6410 Rockledge Dr, Suite 660, Bethesda, MD 20817
Other Locations
AMERICAN ONCOLOGY PARTNERS PA
106 Irving St Nw, Suite 4100, Washington, DC 20010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Biological
Study Drugs: Brentuximab, Nivolumab
Study Phase: Phase 2
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Ibrutinib, Lenalidomide, Rituximab
Study Phase: Phase 1
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 1/Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
Enrollment Status: Terminated
Publish Date: August 01, 2024
Intervention Type: Diagnostic test
View 6 Less Clinical Trials

274 Total Publications

Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Journal: Blood advances
Published: March 13, 2025
Similar Doctors
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Kashif A. Firozvi
Hematology Oncology | Oncology | Hematology
Advanced in Marginal Zone Lymphoma (MZL)
Dr. Kashif A. Firozvi
Hematology Oncology | Oncology | Hematology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (9.7 miles away)
301-933-3216
Languages Spoken:
English, Hindi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Kashif Firozvi is a Hematologist Oncology specialist and an Oncologist in Silver Spring, Maryland. Dr. Firozvi is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Colorectal Cancer, and Familial Colorectal Cancer. Dr. Firozvi is currently accepting new patients.

Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Catherine Broome
Hematology
Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Catherine Broome
Hematology

Mgmc LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (8.4 miles away)
202-444-3700
Languages Spoken:
English
See accepted insurances

Catherine Broome is a Hematologist in Washington, Washington, D.c.. Dr. Broome is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Autoimmune Hemolytic Anemia, Chronic B-Cell Leukemia (CBCL), Thrombocytopenia, Bone Marrow Aspiration, and Splenectomy.

Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Syed S. Nasir
Hematology | Oncology
Distinguished in Marginal Zone Lymphoma (MZL)
Dr. Syed S. Nasir
Hematology | Oncology

University Of Maryland St Joseph Medical Group LLC

7601 Osler Dr, 
Towson, MD 
 (37.6 miles away)
410-337-1379
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cheson's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile